Terms: = Ovarian cancer AND FGFR1OP, FOP, 11116, ENSG00000213066 AND Treatment
5 results:
1. Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPfop).
Smilde BJ; Stockklausner C; Keen R; Whittaker A; Bullock AN; von Delft A; van Schoor NM; Yu PB; Eekhoff EMW
BMC Musculoskelet Disord; 2022 Jun; 23(1):519. PubMed ID: 35650602
[TBL] [Abstract] [Full Text] [Related]
2. Long non-coding RNA NRSN2-AS1 facilitates tumorigenesis and progression of ovarian cancer via miR-744-5p/PRKX axis.
Chen Q; Xie J; Yang Y
Biol Reprod; 2022 Mar; 106(3):526-539. PubMed ID: 34791059
[TBL] [Abstract] [Full Text] [Related]
3. microRNA-485-5p inhibits the progression of hepatocellular carcinoma through blocking the WBP2/Wnt signaling pathway.
Gao J; Dai C; Yu X; Yin XB; Zhou F
Cell Signal; 2020 Feb; 66():109466. PubMed ID: 31706018
[TBL] [Abstract] [Full Text] [Related]
4. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial and recurrent ovarian carcinoma: a single center experience.
Pavlov MJ; Ceranic MS; Latincic SM; Sabljak PV; Kecmanovic DM; Sugarbaker PH
Int J Hyperthermia; 2018 Aug; 34(5):564-569. PubMed ID: 28877609
[TBL] [Abstract] [Full Text] [Related]
5. The Wnt gatekeeper SFRP4 modulates EMT, cell migration and downstream Wnt signalling in serous ovarian cancer cells.
Ford CE; Jary E; Ma SS; Nixdorf S; Heinzelmann-Schwarz VA; Ward RL
PLoS One; 2013; 8(1):e54362. PubMed ID: 23326605
[TBL] [Abstract] [Full Text] [Related]
